Acutaas Chemicals Ltd
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
- Market Cap ₹ 24,879 Cr.
- Current Price ₹ 3,035
- High / Low ₹ 3,069 / 1,059
- Stock P/E 67.9
- Book Value ₹ 204
- Dividend Yield 0.05 %
- ROCE 32.8 %
- ROE 24.6 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 46.3% CAGR over last 5 years
Cons
- Stock is trading at 14.9 times its book value
- Promoter holding has decreased over last 3 years: -6.75%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 160 | 188 | 236 | 240 | 341 | 520 | 617 | 688 | 990 | 1,324 | |
| 137 | 158 | 193 | 198 | 259 | 415 | 493 | 580 | 765 | 841 | |
| Operating Profit | 23 | 31 | 43 | 42 | 81 | 105 | 123 | 108 | 225 | 483 |
| OPM % | 14% | 16% | 18% | 18% | 24% | 20% | 20% | 16% | 23% | 36% |
| 0 | 3 | 1 | 2 | 0 | 3 | 4 | -18 | 18 | 46 | |
| Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 | 3 |
| Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 15 | 24 | 33 |
| Profit before tax | 19 | 28 | 37 | 35 | 72 | 91 | 112 | 69 | 214 | 493 |
| Tax % | 35% | 35% | 33% | 21% | 25% | 21% | 26% | 37% | 25% | 26% |
| 12 | 18 | 25 | 27 | 54 | 72 | 83 | 44 | 160 | 366 | |
| EPS in Rs | 40.17 | 61.43 | 11.73 | 13.08 | 8.57 | 9.87 | 11.43 | 5.92 | 19.48 | 44.73 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% | 25% | 8% | 6% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 29% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | 63% |
| TTM: | 132% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| 1 Year: | 155% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 18% |
| 3 Years: | 19% |
| Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 | 41 |
| Reserves | 38 | 56 | 71 | 97 | 132 | 482 | 550 | 638 | 1,271 | 1,627 |
| 26 | 41 | 54 | 59 | 137 | 1 | 3 | 203 | 11 | 32 | |
| 43 | 56 | 77 | 61 | 110 | 136 | 169 | 193 | 215 | 235 | |
| Total Liabilities | 109 | 155 | 212 | 228 | 410 | 655 | 759 | 1,071 | 1,538 | 1,935 |
| 14 | 15 | 58 | 62 | 161 | 178 | 222 | 357 | 499 | 601 | |
| CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 | 228 |
| Investments | 15 | 21 | 28 | 28 | 33 | 33 | 33 | 68 | 70 | 118 |
| 68 | 89 | 124 | 126 | 216 | 440 | 474 | 521 | 839 | 989 | |
| Total Assets | 109 | 155 | 212 | 228 | 410 | 655 | 759 | 1,071 | 1,538 | 1,935 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 29 | 10 | 22 | 27 | 26 | -10 | 56 | 101 | 116 | 305 | |
| -19 | -27 | -25 | -24 | -100 | -122 | -20 | -337 | -234 | -334 | |
| -7 | 14 | 3 | 0 | 72 | 140 | -14 | 235 | 274 | 4 | |
| Net Cash Flow | 2 | -2 | -0 | 3 | -2 | 8 | 21 | -1 | 155 | -25 |
| Free Cash Flow | 14 | -17 | 4 | 8 | -75 | -42 | -28 | -205 | -75 | 110 |
| CFO/OP | 154% | 58% | 83% | 85% | 50% | 12% | 65% | 109% | 71% | 86% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 97 | 113 | 80 | 127 | 113 | 136 | 113 | 107 | 99 |
| Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 135 | 116 | 147 |
| Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 153 | 119 | 104 | 98 |
| Cash Conversion Cycle | 11 | 31 | 40 | 83 | 78 | 105 | 114 | 129 | 119 | 149 |
| Working Capital Days | 46 | 59 | 23 | 29 | 49 | 139 | 138 | 89 | 122 | 116 |
| ROCE % | 38% | 35% | 27% | 33% | 24% | 21% | 14% | 20% | 33% |
Insights
In beta| Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Export Share of Revenue % |
|
|||||||
| Number of Commercialized Products Numbers |
||||||||
| Number of Customers Numbers |
||||||||
| Installed Production Capacity (MTPA) MTPA |
||||||||
| R&D Headcount Numbers |
||||||||
| Geographical Presence (Countries) Numbers |
||||||||
| Capacity Utilization % |
||||||||
| Installed Production Capacity KL |
||||||||
| Patents Granted Numbers |
||||||||
| Supply Chain: Raw Material Import from China % |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
19 May - ACEPL allotted 1,111 shares to A.R.Z Pharma Ltd., reducing Acutaas stake to 90% on May 19, 2026.
-
Announcement under Regulation 30 (LODR)-Cessation
18 May - Mr. Trilok Vasant Sontakke resigned as Senior General Manager, Technical Support, effective May 15, 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
16 May - Corporate Presentation which shall be discussed at the upcoming Investor Conferences/Meets is herewith enclosed.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 May - Intimation of schedule of Conferences Meet as per details attached.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
6 May - Transcript of Earnings Call for Q4 FY26 Financial Results held on April 30, 2026 is enclosed.
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Apr 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Oct 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
Business Overview
AMI Organics manufactures specialty chemicals with varied end usage, and is focused on development and manufacturing of advanced pharmaceutical intermediates for regulated and generic APIs and New Chemical Entities (NCE), and key starting materials for agrochemical and fine chemicals. [1]